Maxim Group Maintains Buy on Kiora Pharmaceuticals, Lowers Price Target to $2
Portfolio Pulse from jenniferd'souza@benzinga.com
Maxim Group analyst Michael Okunewitch maintains a 'Buy' rating on Kiora Pharmaceuticals (NASDAQ:KPRX), but has lowered the price target from $12 to $2.
August 09, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target, Maxim Group maintains a 'Buy' rating on Kiora Pharmaceuticals, indicating continued confidence in the company's potential.
The lowered price target could potentially lead to a short-term decrease in KPRX's stock price. However, the maintained 'Buy' rating indicates that Maxim Group still sees potential in the company, which could balance out any negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100